What is BeSound?
BeSound is a pioneering healthtech enterprise dedicated to advancing breast cancer screening through innovative ultrasound technology. By assembling a multidisciplinary team of world-renowned scientists, researchers, and clinicians, the company has developed a diagnostic platform that prioritizes patient comfort while maintaining high clinical efficacy. Unlike traditional mammography, BeSound's methodology is specifically engineered to perform effectively on dense breast tissue, a common challenge that often leads to diagnostic ambiguity. By significantly reducing false positives, the company aims to alleviate patient anxiety and streamline the clinical workflow, positioning itself as a transformative force in the early detection of oncological conditions.
How much funding has BeSound raised?
BeSound has raised a total of $6.8M across 1 funding round:
Other Financing Round
$6.8M
Other Financing Round (2025): $6.8M with participation from Overwater Ventures, Kindred Ventures, Muse Capital, and Lux Capital
Key Investors in BeSound
Overwater Ventures
Overwater Ventures partners with pre-seed and seed stage founders who are addressing significant global challenges, providing essential support in commercialization and scaling.
Kindred Ventures
Kindred Ventures is a multi-stage investment firm that leverages deep entrepreneurial experience to support founders across various high-growth technology sectors.
Muse Capital
Muse Capital is an early-stage venture capital firm focused on investing in overlooked and untapped consumer technology opportunities in the sectors of care, play, and living.
What's next for BeSound?
With this major enterprise-level funding, BeSound is poised to enter a phase of rapid commercialization and clinical expansion. The strategic roadmap likely involves scaling its research and development efforts to further optimize its ultrasound algorithms and expanding its footprint within the global healthcare market. As the company moves beyond its initial development stage, the focus will shift toward securing regulatory milestones and establishing partnerships with major hospital networks. This growth trajectory suggests that BeSound is not merely iterating on existing technology but is actively establishing a new standard for diagnostic precision in women's health, ultimately aiming to improve long-term patient outcomes through earlier and more reliable intervention.
See full BeSound company page
